Erratum to (Am J Physiol Renal Physiol (2012), 302, (F1245-F1251), 10.1152/ajprenal.00652.2011);Membrane complement regulators protect against fibrin exudation increases in a severe peritoneal inflammation model in rats

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 10, 2012, Pages

  Mizuno, Masashi ^a   Ito, Yasuhiko ^a   Mizuno, Tomohiro ^a   Harris, Claire L ^b   Suzuki, Yasuhiro ^a   Okada, Noriko ^c   Matsuo, Seiichi ^a   Paul Morgan, B ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Complement regulation; Peritoneal dialysis; Peritonitis; Zymosan

Indexed keywords

CD59 ANTIGEN; FIBRIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SNAKE VENOM; ZYMOSAN;

ABDOMINAL CAVITY INFLAMMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; HOMEOSTASIS; HUMAN; INFLAMMATION; MALE; NAJA; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PERITONITIS; PRIORITY JOURNAL; RAT; RISK FACTOR;

EID: 84861134183     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.zh2-6730-corr.2012     Document Type: Erratum

References (31)

1. Aguilera A, Yáñez-Mo M, Selgas R, Sánchez-Madrid F, López-Cabrera M. Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr Opin Investig Drugs 6: 262-268, 2005.
2. Gupta A, Mi H, Wroe C, Jaques B, Talbot D. Fatal Candida famata peritonitis complicating sclerosing peritonitis in a peritoneal dialysis patient. Nephrol Dial Transplant 21: 2036-2037, 2006.
3. Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 25: S19-S29, 2005.
4. Hughes TR, Piddlesden SJ, Williams JD, Harrison RA, Morgan BP. Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem J 284: 169-176, 1992.
5. Hurst SM, McLoughlin RM, Monslow J, Owens S, Morgan L, Fuller GM, Topley N, Jones SA. Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells. J Immunol 169: 5244-5251, 2002.
6. Kawanishi H, Moriishi M. Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int 25: S14-S18, 2005.
7. Kawanishi H, Moriishi M, Tsuchiya S. Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery. Adv Perit Dial 22: 60-64, 2006.
8. Kuriyama S, Tomonari H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transplant 16: 1304-1305, 2001.
9. Masunaga Y, Muto S, Asakura S, Akimoto T, Homma S, Kusano E, Asano Y. Ascites from patients with encapsulating peritoneal sclerosis augments NIH/3T3 fibroblast proliferation. Ther Apher Dial 7: 486-493, 2003.
10. Mizuno M, Cole DS. Novel C5a regulators in inflammation. Expert Opin Investig Drugs 14: 807-821, 2005.
11. Mizuno M, Harris CL, Johnson PM, Morgan BP. Rat membrane cofactor protein (MCP; CD46) is expressed only in the acrosome of developing and mature spermatozoa and mediates binding to immobilized activated C3. Biol Reprod 71: 1374-1383, 2004.
12. Mizuno M, Harris CL, Morgan BP. Spermatogenic cells distal to the blood-testis barrier in rats lack C3 convertase regulators and may be at risk of complement-mediated injury. J Reprod Immunol 69: 23-34, 2006.
13. Mizuno M, Ito Y, Tanaka A, Hiramatsu H, Ito I, Watanabe M, Tsuruta Y, Matsuoka T, Danbara A, Tamai H, Kasuga H, Shimizu H, Kurata H, Inaguma D, Hiramatsu T, Horie M, Naruse T, Maruyama S, Yuzawa Y, Matsuo S. Status of peritoneal dialysis patients and peritonitis in the Tokai area of Japan. Clin Exp Nephrol 15: 727-737, 2011.
14. Mizuno M, Ito Y, Hepburn N, Mizuno T, Noda Y, Yuzawa Y, Harris CL, Morgan BP, Matsuo S. Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injuries accompanied by complement activation in a rat peritonitis model. J Immunol 183: 1403-1412, 2009.
15. Mizuno M, Morgan BP. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases. Curr Drug Targets Inflamm Allergy 3: 85-94, 2004.
16. Mizuno M, Morgan BP. An update on the roles of the complement system in autoimmune diseases and the therapeutic possibilities of anticomplement agents. Curr Drug Ther 6: 35-50, 2011.
17. Mizuno M, Nishikawa K, Okada N, Matsuo S, Okada H, Ito K, Okada H. Functional inhibition of a membrane complement regulatory protein induces lethal shock in rats primed with trace levels of lipopolysaccharide. J Immunol 162: 5477-5482, 1999.
18. Mizuno M, Nishikawa K, Goodfellow RM, Piddlesden SJ, Morgan BP, Matsuo S. The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats. Arthritis Rheum 40: 527-533, 1997.
19. Mizuno M, Nozaki M, Morine N, Suzuki N, Nishikawa K, Morgan BP, Matsuo S. A protein toxin from the sea anemone Phyllodiscus semoni targets the kidney and causes a renal injury resembling haemolytic uremic syndrome. Am J Pathol 171: 402-414, 2007.
20. Mizuno T, Mizuno M, Morgan BP, Noda Y, Yamada K, Okada N, Yuzawa Y, Matsuo S, Ito Y. Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrol Dial Transplant 22: 1821-1830, 2010.
21. Mizutani M, Ito Y, Mizuno M, Nishimura H, Suzuki Y, Hattori R, Matsukawa Y, Imai M, Oliver N, Goldshmeding R, Aten J, Krediet R, Yuzawa Y, Matsuo S. Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. Am J Physiol Renal Physiol 298: F721-F733, 2010.
22. Miyazaki M, Yuzawa Y. The role of peritoneal fibrosis in encapsulating peritoneal sclerosis. Perit Dial Int 25: S48-S56, 2005.
23. Moustafellos P, Hadjianastassiou V, Roy D, Velzeboer NE, Maniakyn N, Vaidya A, Friend PJ. Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc 38: 2913-2914, 2006.
24. Nagappan R, Collins JF, Lee WT. Fungal peritonitis in continuous ambulatory peritoneal dialysis-the Auckland experience. Am J Kidney Dis 20: 492-496, 1992.
25. Nessim SJ, Perl J, Bargman JM. The renin-angiotensin-aldosterone system in peritoneal dialysis: Is what is good for the kidney also good for the peritoneum? Kidney Int 78: 23-28, 2010.
26. Nishimura M, Ito Y, Mizuno M, Tanaka A, Morita Y, Maruyama S, Yuzawa Y, Maruyama S. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol Renal Physiol 294: F1084-F1093, 2008.
27. Patel P, Sekiguchi Y, Oh KH, Patterson SE, Kolb MR, Margetts PJ. Smad3-dependent and-independent pathways are involved in peritoneal membrane injury. Kidney Int 77: 319-328, 2010.
28. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L; ISPD Ad Hoc Advisory Committee. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 25: 107-131, 2005.
29. Ponda MP, Hostetter TH. Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol 1: 668-677, 2006.
30. Rawal N, Pangburn MK. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme. J Biol Chem 273: 16828-16835, 1998.
31. Ricklin D, Hajishengalis G, Yang K, Lambris JD. Complement: A key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797, 2010.